[Bemetil pharmacokinetics in an experiment on rats]

Area of Science:

• Pharmacology
• Drug Metabolism
• Toxicology

Background:

• Bepmetil (2-ethyl-mercaptobenzimidazole) is an actoprotector with limited pharmacokinetic data.
• Understanding drug absorption, distribution, metabolism, and excretion (ADME) is crucial for therapeutic efficacy.

Purpose of the Study:

• To determine the pharmacokinetic profile of bemetil following intravenous and intragastric administration in rats.
• To calculate key pharmacokinetic parameters and bioavailability using a two-compartment model.
• To investigate the urinary excretion pathways of bemetil and its metabolites.

Main Methods:

• Pharmacokinetic study in rats using intravenous and intragastric administration.
• Gas-liquid chromatography for drug quantification in biological samples.
• Application of a two-compartment model for pharmacokinetic parameter estimation.
• Analysis of urinary bemetil excretion.

Main Results:

• Bepmetil rapidly entered systemic circulation after intragastric administration, reaching peak concentrations within one hour.
• Biexponential elimination kinetics were observed for bemetil in blood following both administration routes.
• The two-compartment model allowed for the calculation of essential pharmacokinetic constants and bioavailability.
• Urinary analysis revealed minimal unchanged bemetil excretion (0.56%), with most excreted as metabolites or in bound forms.

Conclusions:

• Bepmetil exhibits rapid oral absorption and a biexponential elimination pattern in rats.
• The drug is extensively metabolized, with limited unchanged bemetil excreted renally.
• Pharmacokinetic data supports further investigation into bemetil's therapeutic applications and safety profile.